Forte Biosciences (FBRX) Liabilities and Shareholders Equity (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $67.2 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $67.2 million, up 41.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $354.9 million (up 131.88% YoY), and the FY2025 annual result was $82.8 million, up 34.47% from the prior year.
• Liabilities and Shareholders Equity retreated to $67.2 million in Q1 2026 per FBRX's latest filing, from $82.8 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $107.8 million in Q2 2025 and troughed at $17.9 million in Q3 2024.
• A 5-year average of $50.8 million and a median of $42.0 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity slumped 62.52% in 2024, then surged 441.01% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $42.0 million in 2022, then declined by 7.18% to $39.0 million in 2023, then soared by 57.93% to $61.6 million in 2024, then jumped by 34.47% to $82.8 million in 2025, then declined by 18.79% to $67.2 million in 2026.
• Business Quant data shows FBRX's Liabilities and Shareholders Equity at $67.2 million in Q1 2026, $82.8 million in Q4 2025, and $97.1 million in Q3 2025.